Free Trial
NASDAQ:CGTX

Cognition Therapeutics (CGTX) Stock Price, News & Analysis

Cognition Therapeutics logo
$2.81 +0.82 (+41.21%)
Closing price 04:00 PM Eastern
Extended Trading
$2.80 0.00 (-0.18%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cognition Therapeutics Stock (NASDAQ:CGTX)

Key Stats

Today's Range
$2.01
$2.87
50-Day Range
$0.26
$2.02
52-Week Range
$0.22
$2.87
Volume
20.83 million shs
Average Volume
4.73 million shs
Market Capitalization
$206.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.83
Consensus Rating
Buy

Company Overview

Cognition Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

CGTX MarketRank™: 

Cognition Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 335th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cognition Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cognition Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cognition Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cognition Therapeutics are expected to grow in the coming year, from ($0.80) to ($0.67) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cognition Therapeutics is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cognition Therapeutics is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cognition Therapeutics has a P/B Ratio of 28.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.68% of the float of Cognition Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cognition Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cognition Therapeutics has recently decreased by 28.21%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cognition Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cognition Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.68% of the float of Cognition Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cognition Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cognition Therapeutics has recently decreased by 28.21%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cognition Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Cognition Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    40 people have searched for CGTX on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.40% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cognition Therapeutics' insider trading history.
Receive CGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CGTX Stock News Headlines

Equities Analysts Issue Forecasts for CGTX FY2025 Earnings
Elon Musk’s New Technology
Elon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth.tc pixel
See More Headlines

CGTX Stock Analysis - Frequently Asked Questions

Cognition Therapeutics' stock was trading at $0.7013 at the beginning of 2025. Since then, CGTX shares have increased by 300.7% and is now trading at $2.81.

Cognition Therapeutics, Inc. (NASDAQ:CGTX) issued its earnings results on Thursday, August, 7th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01.

Cognition Therapeutics (CGTX) raised $45 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 3,768,116 shares at a price of $11.00-$13.00 per share.

Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cognition Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Eli Lilly and Company (LLY), Meta Platforms (META), GE Aerospace (GE), Arista Networks (ANET) and Celestica (CLS).

Company Calendar

Last Earnings
8/07/2025
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGTX
CIK
1455365
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$4.00
Low Price Target
$1.50
Potential Upside/Downside
+0.8%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$33.97 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-251.23%
Return on Assets
-130.75%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.54
Quick Ratio
1.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
28.10

Miscellaneous

Outstanding Shares
73,470,000
Free Float
62,892,000
Market Cap
$206.45 million
Optionable
Not Optionable
Beta
1.00

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CGTX) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners